Regenacy Revenue and Competitors

Boston, MA USA

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Regenacy's estimated annual revenue is currently $1.7M per year.(i)
  • Regenacy's estimated revenue per employee is $155,000

Employee Data

  • Regenacy has 11 Employees.(i)
  • Regenacy grew their employee count by -15% last year.

Regenacy's People

NameTitleEmail/Phone
1
VP Regulatory AffairsReveal Email/Phone
2
Chief Financial OfficerReveal Email/Phone
3
President and CEOReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.2M67-45%$107.3MN/A
#2
$0.3M20%N/AN/A
#3
$5.1M336%N/AN/A
#4
$11.9M77-37%$312.8MN/A
#5
$0.9M60%N/AN/A
#6
$235M300-5%$340.9MN/A
#7
$45.9M237-7%$7.6MN/A
#8
$3.9M5035%N/AN/A
#9
$5.4M353%N/AN/A
#10
$1.6M100%N/AN/A
Add Company

What Is Regenacy?

Regenacy Pharmaceuticals is developing a novel, disease-modifying approach to treating peripheral neuropathies that goes beyond pain and symptom management to restore peripheral nerve function. Our lead compound ricolinostat (ACY-1215) is an oral, selective inhibitor of the microtubule modifying enzyme HDAC6 with first-in-class potential, currently positioned to enter Phase 2 clinical trials. Our investigation of ricolinostat for diabetic, chemotherapy-induced and inherited peripheral neuropathies is based on compelling proof-of-concept preclinical studies demonstrating restoration of normal nerve function. We were founded in December 2016 following the acquisition of Acetylon Pharmaceuticals by Celgene. Regenacy received exclusive rights to ricolinostat, a clinical stage, orally bioavailable, HDAC6 selective inhibitor, for a range of non-cancer disease indications. We also have a unique and proprietary portfolio of selective HDAC1,2 inhibitors with potential for treating cancer, hemoglobinopathies, and cognitive dysfunction.

keywords:N/A

N/A

Total Funding

11

Number of Employees

$1.7M

Revenue (est)

-15%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Regenacy News

2022-04-17 - Global & US Chemotherapy Induced Peripheral Neuropathy ...

... Treatment Market Benefit and Volume 2022 with Status and Prospect to 2028 | Aptinyx Inc., Regenacy Pharmaceuticals, MAKScientific LLC.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$1M1110%N/A
#2
$1.7M110%N/A
#3
$1.6M12N/AN/A
#4
$1.9M1233%N/A
#5
$1.6M12-14%N/A